Effects of synthetic A3 adenosine receptor agonists on cell proliferation and viability are receptor independent at micromolar concentrations

Journal of Physiology and Biochemistry

Volumn 69, Issue 3, 2013, Pages 405-417

  Mlejnek, Petr ^a   Dolezel, Petr ^a   Frydrych, Ivo ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

A3 adenosine agonist; Akt; Apoptosis; CHO cells; Cl IB MECA; Erk1 2; IB MECA; Necrosis

Indexed keywords

2 CHLORO N 6 (3 IODOBENZYL) ADENOSINE 5' N METHYLURONAMIDE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE RECEPTOR STIMULATING AGENT; CASPASE 3; CASPASE 7; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL DEATH; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHINESE HAMSTER; CHO CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

CRICETULUS GRISEUS;

EID: 84887606357     PISSN: 11387548     EISSN: 18778755     Source Type: Journal    
DOI: 10.1007/s13105-012-0222-7     Document Type: Article

References (48)

1. Abbracchio MP, Burnstock G (1998) Purinergic signalling: pathophysiological roles. Jpn J Pharmacol 78:113-145
2. Appel E, Kazimirski G, Ashkenazi E, Kim SG, Jacobson KA, Brodie C (2001) Roles of BCL-2 and caspase 3 in the adenosine A3 receptor-induced apoptosis. J Mol Neurosci 17:285-292
3. Bar-Yehuda S, Madi L, Barak D, Mittelman M, Ardon E, Ochaion A, Cohn S, Fishman P (2002) Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents. Exp Hematol 30:1390-1398
4. 3 adenosine receptor: pharmacology and role in disease, 193rd edn. Springer, Heidelberg, pp 297-327
5. Brambilla R, Cattabeni F, Ceruti S, Barbieri D, Franceschi C, Kim YC, Jacobson KA, Klotz KN, Lohse MJ, Abbracchio MP (2000) Activation of the A3 adenosine receptor affects cell cycle progression and cell growth. Naunyn Schmiedebergs Arch Pharmacol 361:225-234
6. Darzynkiewitcz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F (1992) Features of apoptotic cells measured by flow-cytometry. Cytometry 13:795-808
7. 6-benzyladenosine decreases its cytotoxicity in human leukemia cells. Toxicol in Vitro 24:2079-2083
8. Fishman P, Bar-Yehuda S, Farbstein T, Barer F, Ohana G (2000) Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptors. J Cell Physiol 183:393-398
9. Fishman P, Bar-Yehuda S, Madi L, Cohn I (2002) A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 13:437-443
10. Fishman P, Bar-Yehuda S, Synowitz M, Powell JD, Klotz KN, Gessi S, Borea PA (2009) Adenosine receptors and cancer. In: Wilson CN, Mustafa SJ (eds) Handb Exp Pharmacol, 193rd edn. Springer-Verlag, Berlin, Heilderberg, pp 399-441
11. Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L, Khalili K (2002) Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene 21:4060-4064
12. Fredholm BB (2007) Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 14:1315-1323
13. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M (1994) Nomenclature and classification of purinoceptors. Pharmacol Rev 46:143-156
14. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W (2000) Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 362:364-374
15. Fredholm BB, Irenius E, Kull B, Schulte G (2001) Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 61:443-448
16. Frydrych I, Mlejnek P, Dolezel P (2009) Cyclosporin A sensitises Bcr-Abl positive cells to imatinib mesylate independently of P-glycoprotein expression. Toxicol in Vitro 23:1482-1490
17. 6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. J Med Chem 37:636-646
18. Gao Z, Li BS, Day YJ, Linden J (2001) A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol Pharmacol 59:76-82
19. Gessi S, Merighi S, Varani K, Leung E, MacLennan S, Borea PA (2008) The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 117:123-140
20. Hammarberg C, Fredholm BB, Schulte G (2004) Adenosine A3 receptor-mediated regulation of p38 and extracellularregulated kinase ERK1/2 via phosphatidylinositol-3'-kinase. Biochem Pharmacol 67:129-134
21. Jacobson KA (1998) Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 19:184-191
22. Kamiya H, Kanno T, Fujita Y, Gotoh A, Nakano T, Nishizaki T (2012) Apoptosis-related gene transcription in human A549 lung cancer cells via A3 adenosine receptor. Cell Physiol Biochem 29:687-696
23. 6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. J Med Chem 37:3614-3621
24. Kim TH, Kim YK, Woo JS (2012) The adenosine A3 receptor agonist Cl-IB-MECA induces cell death through Ca +/ROS-dependent down regulation of ERK and Akt in A172 human glioma cells. Neurochem Res. doi:10.1007/s11064-012-0855-5
25. Kim SJ, Min HY, Chung HJ, Park EJ, Hong JY, Kang YJ, Shin DH, Jeong LS, Lee SK (2008) Inhibition of cell proliferation through cell cycle arrest and apoptosis by thio-Cl-IB-MECA, a novel A3 adenosine receptor agonist, in human lung cancer cells. Cancer Lett 264:309-315
26. Kim SG, Ravi G, Hoffmann C, Jung YJ, Kim M, Chen A, Jacobson KA (2002) p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA. Biochem Pharmacol 63:871-880
27. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ (1998) Comparative pharmacology of human adenosine receptor subtypes- characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 357:1-9
28. Kohno Y, Sei Y, Koshiba M, Kim HO, Jacobson KA (1996) Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A (3) receptor agonists. Biochem Biophys Res Commun 219:904-910
29. Lee EJ, Min HY, Chung HJ, Park EJ, Shin DH, Jeong LS, Lee SK (2005) A novel adenosine analog, thio-Cl-IB-MECA, induces G0/G1 cell cycle arrest and apoptosis in human promyelocytic leukemia HL-60 cells. Biochem Pharmacol 70:918-924
30. Lu J, Pierron A, Ravid K (2003) An adenosine analogue, IB-MECA, down-regulates estrogen receptor alpha and suppresses human breast cancer cell proliferation. Cancer Res 63:6413-6423
31. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, Borea PA (2003) A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 100:31-48
32. Mlejnek P (2001) Caspase inhibition and N (6)-benzyladenosineinduced apoptosis in HL-60 cells. J Cell Biochem 83:678-689
33. Mlejnek P, Kolman A (1999) Effects of three epoxides, ethylene oxide, propylene oxide and epichlorohydrin, on cell cycle progression and cell death in human diploid fibroblasts. Chem Biol Interact 117:219-239
34. Mlejnek P, Dolezel P (2010) Induction of apoptosis by A3 adenosine receptor agonist N-(3-iodobenzyl)-adenosine-5'-N-methylcarboxamide in human leukemia cells: a possible involvement of intracellular mechanism. Acta Physiologica 199:171-179
35. 6-(3-iodobenzyl)- adenosine-5'-N-methyluronamide in human leukemia cells. J Cell Physiol 227:676-685
36. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
37. Morello S, Petrella A, Festa M, Popolo A, Monaco M, Vuttariello E, Chiappetta G, Parente L, Pinto A (2008) Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation. Cancer Biol Ther 7:278-284
38. Nishida E, Gotoh Y (1993) The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci 18:128-131
39. Ohana G, Bar-Yehuda S, Barer F, Fishman P (2001) Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. J Cell Physiol 186:19-23
40. Otsuki T, Kanno T, Fujita Y, Tabata C, Fukuoka K, Nakano T, Gotoh A (2012) A3 adenosine receptor-mediated p53-dependent apoptosis in Lu-65 human lung cancer cells. Cell Physiol Biochem 30:210-220
41. Robinson AJ, Dickenson JM (2001) Regulation of p42/p44 MAPK and p38 MAPK by the adenosine A (1) receptor in DDT (1) MF-2 cells. Eur J Pharmacol 413:151-161
42. Schulte G, Fredholm BB (2000) Human adenosine A (1), A (2A), A (2B), and A (3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol Pharmacol 58:477-482
43. Schulte G, Fredholm BB (2002) Signaling pathway from the human adenosine A (3) receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2. Mol Pharmacol 62:1137-1146
44. Shainberg A, Safran N, Balas N, Zinman T, Isaac A, Schwab K, Akabayov B, Shneyvays V (2000) The role of A1/A3 adenosine receptor activation in reduction of cardiomyocyte injury caused by hypoxic stress and in induction of apoptosis in rat cardiomyocyte cultures. Adv Exp Med Biol 486:201-205
45. Shneyvays V, Jacobson KA, Li A-H, Nawrath H, Zinman T, Isaac A, Shainberg A (2000) Induction of apoptosis in rat cardiocytes by A3 adenosine receptor activation and its suppression by isoproterenol. Exp Cell Res 257:111-126
46. Shneyvays V, Mamedova LK, Korkus A, Shainberg A (2002) Cardiomyocyte resistance to doxorubicin mediated by A (3) adenosine receptor. J Mol Cell Cardiol 34:493-507
47. Shneyvays V, Nawrath H, Jacobson KA, Shainberg A (1998) Induction of apoptosis in cardiac myocytes by an A3 adenosine receptor agonist. Exp Cell Res 243:383-397
48. Von Lubitz DK, Lin RC, Popik P, Carter MF, Jacobson KA (1994) Adenosine A3 receptor stimulation and cerebral ischemia. Eur J Pharmacol 263:59-67